DexCom Inc.DXCM
Health Care · Health Care Equipment & Services · NASDAQ · United States · dexcom.com
DexCom, Inc. is a U.S. medical device company focused on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for people living with diabetes. Headquartered in San Diego, California, DexCom's CGM systems enable real-time glucose data display and alerts without routine fingersticks, improving diabetes management outcomes.
Key ratios
Operating cash flow growth
77.1%TTM
2025
45.6%2024
32.2%2023
11.8%
EPS growth
77.4%TTM
2025
46.7%2024
9.4%2023
58.1%
FCF / Sales
28.3%TTM
2025
23.1%2024
15.6%2023
14.1%
Net margin
20.1%TTM
2025
17.9%2024
14.3%2023
15.0%
ROA
10.3%TTM
2025
8.9%2024
5.9%2023
6.4%
ROE
34.5%TTM
2025
34.5%2024
27.6%2023
25.8%
Revenue growth
15.5%TTM
2025
15.6%2024
11.3%2023
24.5%
Recent news
Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
Dexcom Reports First Quarter 2026 Financial Results
Track DXCM in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer